Hemispherx Biopharma appoints Ellen Lintal as chief accountant
Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Tom Equels tells Proactive Investors the biotech company has promoted Ellen Lintal as its new chief accounting officer, from vice-president of finance and control.
Equels says Lintal has experience with M&A, which Equels says, will advance the company's business plan.
Quick facts: AIM ImmunoTech Inc.
Market Cap: $5.13 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE